Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.57 |
| ▸ | MERTK | Q12866 | 2/20 | 0.57 |
| ▸ | JAK3 | P52333 | 4/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.53 |
| ▸ | JAK2 | O60674 | 3/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.52 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 4/20 | 0.51 |
| ▸ | YES1 | P07947 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 4/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | INSR | P06213 | 2/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | JAK1 | P23458 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038823 | 0.91 | SYK (0.57) | AXLMERTKJAK3BRD4JAK2 | |
| SCHEMBL1038446 | 0.91 | ALK (0.63) | AXLMERTKJAK3BRD4JAK2 | |
| SCHEMBL1038670 | 0.90 | AXL (0.63) | AXLMERTKJAK3BRD4JAK2 | |
| SCHEMBL12726508 | 0.87 | ALK (0.62) | AXLMERTKJAK3ALKFLT3 | |
| SCHEMBL12765475 | 0.83 | EGFR (0.59) | AXLMERTKALKFLT3SYK | |
| SCHEMBL12726373 | 0.81 | GLO1 (0.59) | AXLMERTKJAK3BRD4JAK2 | |
| SCHEMBL1037400 | 0.81 | ALK (0.56) | AXLMERTKALKFLT3MET | |
| SCHEMBL12726512 | 0.81 | ALK (0.63) | AXLJAK3BRD4ALKFLT3 | |
| SCHEMBL1037854 | 0.80 | GLO1 (0.60) | AXLMERTKJAK3BRD4JAK2 | |
| SCHEMBL1039454 | 0.79 | LRRK2 (0.46) | AXLMERTKJAK3BRD4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | AXL 2346/4885MERTK 381/4885JAK3 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.